((自动化翻译由路透提供，请见免责声明 )) (更新)
12月20日 - ** 药物开发商Galectin Therapeutics 股价下跌56.2%，跌至八年来的最低点87美分
** 该公司用于治疗代谢功能障碍相关性脂肪性肝炎（metabolic dysfunction associated steatohepatitis(MASH)）的实验性药物贝拉苷（belapectin）在一项临床试验中未能达到主要目标。
** 公司正在对 355 名因 MASH 导致肝脏瘢痕和门静脉高血压的患者进行贝拉果胶试验
** 该药物在减少食管静脉曲张或食管中可导致出血的扩张静脉--GALT--的主要目标方面未达到统计学意义
** 与安慰剂相比，该药物有助于将食管静脉曲张发生率降低 43.2%，但 "综合终点未达到统计学意义"。
** 贝拉肽的安全性仍然非常令人鼓舞，在试验中未报告与药物相关的严重不良事件- GALT
** 公司表示将在 2025 年初提供更多数据，并确定开发贝拉胶原蛋白的下一步计划
** 包括盘中走势在内，该股今年累计下跌 51.3
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.